---
layout: post
title: "Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update"
date: 2026-02-19T12:00:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/insmed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-302691904.html
significance: 9.00
---

<p>—Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million— —Total Company Revenues of $606.4 Million for Full-Year 2025—...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/insmed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-302691904.html)

**Published:** 2026-02-19 12:00:00 +0000

**Significance Score:** 9.00

[View original](https://www.prnewswire.com/news-releases/insmed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-302691904.html)
